Readoutin 76d
CanSino Biologics Inc. — PCV13i
Phase 3 primary completion: A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks).
- Date
- Feb 2027
- Type
- Readout
- Indication
- Pneumococcal Infections